Eli Lilly and - LLY Stock Forecast, Price & News

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Trading Up 0.4 %

Eli Lilly and stock opened at $302.50 on Tuesday. Eli Lilly and has a 52 week low of $220.20 and a 52 week high of $335.33. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.85 and a current ratio of 1.10. The firm has a market capitalization of $287.43 billion, a PE ratio of 48.25, a PEG ratio of 2.25 and a beta of 0.35. The business's 50-day simple moving average is $315.68 and its 200-day simple moving average is $290.06.

Eli Lilly and (NYSE:LLY - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The firm had revenue of $6.49 billion for the quarter, compared to the consensus estimate of $6.85 billion. During the same quarter in the prior year, the firm earned $1.87 earnings per share. The company's revenue was down 3.7% on a year-over-year basis. Equities research analysts forecast that Eli Lilly and will post 7.98 earnings per share for the current year.

Eli Lilly and Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 9th. Shareholders of record on Monday, August 15th will be issued a dividend of $0.98 per share. This represents a $3.92 dividend on an annualized basis and a yield of 1.30%. The ex-dividend date is Friday, August 12th. Eli Lilly and's payout ratio is 62.52%.

Analyst Ratings Changes

Several analysts have recently commented on LLY shares. Barclays raised their target price on Eli Lilly and from $333.00 to $355.00 and gave the stock an "overweight" rating in a research report on Thursday, July 7th. Mizuho raised their target price on Eli Lilly and from $315.00 to $356.00 in a research report on Monday, May 2nd. SVB Leerink started coverage on Eli Lilly and in a research report on Monday, May 23rd. They set an "outperform" rating and a $341.00 price objective for the company. Wells Fargo & Company lifted their price objective on Eli Lilly and from $280.00 to $305.00 in a research report on Friday, April 29th. Finally, StockNews.com cut Eli Lilly and from a "strong-buy" rating to a "buy" rating in a research report on Friday. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $316.06.

Insider Buying and Selling at Eli Lilly and

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 215,000 shares of Eli Lilly and stock in a transaction that occurred on Friday, June 24th. The stock was sold at an average price of $324.31, for a total transaction of $69,726,650.00. Following the sale, the insider now directly owns 104,203,810 shares of the company's stock, valued at $33,794,337,621.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 215,000 shares of Eli Lilly and stock in a transaction that occurred on Friday, June 24th. The stock was sold at an average price of $324.31, for a total transaction of $69,726,650.00. Following the sale, the insider now directly owns 104,203,810 shares of the company's stock, valued at $33,794,337,621.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, June 1st. The shares were sold at an average price of $313.44, for a total value of $313,440.00. Following the sale, the chief accounting officer now directly owns 6,274 shares in the company, valued at $1,966,522.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,195,396 shares of company stock valued at $380,134,601. 0.12% of the stock is currently owned by corporate insiders.